'%2F%3E%3Cpath%20d%3D'M11%205H21M13.5%205V11.6A8.5%208.5%200%201%200%2018.5%2011.6V5'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'3.4'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Cpath%20d%3D'M10.6%2019.6L13.9%2021.8L17.6%2018.4L21.4%2020.4'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'2.6'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Ccircle%20cx%3D'17.6'%20cy%3D'18.4'%20r%3D'2.6'%20fill%3D'%23fff'%2F%3E%3C%2Fsvg%3E){kind=small}
Aptus Pharma Limited
APPL (BSE 544529) · ISIN INE15XJ01010 · Pharmaceuticals · Est. 2010 · listed 2025 · website
Open the full company file Every section, filings and your notes, in the app.
Quarterly results
No quarterly results stored for this company yet.
Balance sheet
| As of | Total equity | Borrowings | Total assets |
|---|---|---|---|
| 30 Sep 2026 standalone | ₹28.42 cr | ₹12.11 cr | ₹54.55 cr |
| 31 Mar 2026 standalone | ₹23.35 cr | ₹7.18 cr | ₹43.53 cr |
| 30 Sep 2025 standalone | ₹21.7 cr | ₹8.14 cr | ₹39.59 cr |
Shareholding
| Promoter | FII | DII | Public |
|---|---|---|---|
| 72.89% | — | — | 27.11% |
Latest filings
- Intimation of investor presentation under regulation 30 of SEBI (LODR) Regulations, 2015 21 August 2026 · BSE
- Annual Report FY2025-26 (New) 21 August 2026 · BSE
- Announcement Under Regulation 30 (LODR): Investor Presentation 29 May 2026 · BSE
- Press release on Financial Results for the Half Year and Year ended on 31st March, 2026. 28 April 2026 · BSE
- Audited Financial Results for the half Year and Year ended on 31st March, 2026. 27 April 2026 · BSE
Other companies in Pharmaceuticals
- Lupin Limited
- Sun Pharmaceutical Industries Limited
- Torrent Pharmaceuticals Limited
- Zydus Lifesciences Limited
- Ajanta Pharma Limited
- Alivus Life Sciences Limited
- Wockhardt Limited
- Morepen Laboratories Limited
Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 30 September 2026.
Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.